TRAFALGAR INTERNATIONAL, INC.
Close on Oct 16, 2026
- Market cap
- $1.13M
- P/E (TTM)
- –
- Dividend yield
- –
About Trafalgar International
Pharmaceutical Preparations, SIC 2834
The Greater Cannabis Company, Inc. is a biopharmaceutical company engaged in the development and commercialization of cannabinoid therapeutics. The company focuses on clinical-stage programs licensed from Shaare Zedek Scientific Ltd. to develop therapies targeting neuropsychiatric and neurological disorders, including autism, schizophrenia, Parkinson's disease, and Alzheimer's disease. Its operations emphasize research and development, preclinical studies, and preparing for clinical trials in collaboration with institutional research partners.
The company operates primarily through research partnerships and regulatory pathways in Israel and the United States, having received clearance from the Israel Ministry of Health to proceed with a Phase II clinical study. It maintains an executive office located in Baltimore, Maryland, and has one full-time service provider who serves as its chief executive officer.
Summary of the business section of Trafalgar International's latest annual report, written by StockData.
Company profile
Company
- Legal name
- TRAFALGAR INTERNATIONAL, INC.
- Founded
- 2014
- Headquarters
- Miami, FL
- Address
- 200 South Biscayne Blvd Fl 20 33131
- Phone
- (443) 738-4051
- Employees
- 2, Dec 31, 2020
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Florida
- Fiscal year ends
- December 31
- Auditor
- ALOBA, AWOMOLO & PARTNERS, Floor 4, Providence Court, Ajibade Bus Stop, Beside CocaCola Ibadan Oyo State, Nigeria
Stock & identifiers
- Ticker
- GCAN
- Other tickers
- GCAND
- Shares outstanding
- 1M, Aug 14, 2026
- Public float
- $586.11K, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-5 reverse, Sep 17, 2026; 1-for-5 reverse, Sep 17, 2026; 1-for-1400 reverse, Aug 14, 2026; 1-for-1499 reverse, Nov 12, 2025; 1-for-1500 reverse, Oct 17, 2025
- SEC CIK
- 1695473
- EIN
- 30-0842570
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Talavera Porfirio Sanchez | CEO, Chairman of the Board, Director | 1,000 |
| Aitan Zacharin | Chief Executive Officer, Director | – |
Employees
Headcount reported in annual reports
“We have two persons providing us services on a full-time basis – our chief executive officer and our general counsel.”
Corporate history
Events identified from SEC filings